Brief: Biophytis Presents Preclinical Efficacy Data For Sarconeos (Bio101) In Spinal Muscular Atrophy
16/06/2022 07:04
June 16 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS PRESENTS PRECLINICAL EFFICACY DATA FOR SARCONEOS
(BIO101) IN SPINAL MUSCULAR ATROPHY (SMA), A RARE NEUROMUSCULAR
DISEASE
* PREPARING START OF MYODA CLINICAL PROGRAM IN DUCHENNE
MUSCULAR
DYSTROPHY FOR LATE 2022/EARLY 2023
Source text for Eikon: ID:nEQ4h5dxda
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon